Diamond Biotechnology Balance Sheet Health
Financial Health criteria checks 4/6
Diamond Biotechnology has a total shareholder equity of NT$329.4M and total debt of NT$319.3M, which brings its debt-to-equity ratio to 96.9%. Its total assets and total liabilities are NT$779.2M and NT$449.7M respectively. Diamond Biotechnology's EBIT is NT$64.7M making its interest coverage ratio 12.5. It has cash and short-term investments of NT$64.2M.
Key information
96.9%
Debt to equity ratio
NT$319.29m
Debt
Interest coverage ratio | 12.5x |
Cash | NT$64.19m |
Equity | NT$329.44m |
Total liabilities | NT$449.73m |
Total assets | NT$779.17m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6815's short term assets (NT$370.4M) exceed its short term liabilities (NT$269.8M).
Long Term Liabilities: 6815's short term assets (NT$370.4M) exceed its long term liabilities (NT$180.0M).
Debt to Equity History and Analysis
Debt Level: 6815's net debt to equity ratio (77.4%) is considered high.
Reducing Debt: 6815's debt to equity ratio has increased from 14.3% to 96.9% over the past 5 years.
Debt Coverage: 6815's debt is well covered by operating cash flow (43.4%).
Interest Coverage: 6815's interest payments on its debt are well covered by EBIT (12.5x coverage).